Schrödinger vs XtalPi (2026)
Both combine physics based modeling with machine learning, and they sell it differently. Schrödinger licenses simulation software, including Glide, FEP+ and LiveDesign, that a team runs on its own programs, and develops a pipeline of its own on the same platform. XtalPi, listed in Hong Kong since 2025, runs discovery as a service: a multi agent system plans experiments, more than 200 AI models trained on its own compound and reaction data propose candidates, physics methods such as free energy perturbation and crystal structure prediction check them, and robotic labs run synthesis, crystallization and assays around the clock. Schrödinger is software you operate; XtalPi is a partner that operates the loop, from target to preclinical candidate.
- Physics based simulation software a team licenses and runs itself: Maestro, Glide, FEP+, LiveDesign and BioLuminate.
- Machine learning paired with physics, including an ML module in LiveDesign for predictive models on a team's own data.
- A therapeutics pipeline of its own built on the same platform, and a materials science line beside it.
- A closed loop of AI models, physics methods and robotic laboratories run by the vendor.
- Crystal structure prediction and free energy methods alongside more than 200 models trained on its own data.
- Services and partnerships that take a program from target to preclinical candidate.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Schrödinger and XtalPi are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Schrödinger | XtalPi |
|---|---|---|
| Primary category | Drug Discovery AI | Drug Discovery AI |
| Founded | Not recorded | 2015 |
| Headquarters | New York, NY | Shenzhen, China and Boston, MA |
| Website | schrodinger.com | en.xtalpi.com |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Computational chemistry software company (Nasdaq: SDGR) whose physics based molecular simulation platform is licensed to pharmaceutical, biotechnology, industrial and academic organizations, alongside a proprietary therapeutics pipeline built on the same platform.
Source: AI Health Index, September 2026
XtalPi is a drug and materials discovery company founded in Boston in 2015 by three MIT postdoctoral physicists, headquartered in Shenzhen and listed on the Hong Kong Stock Exchange (2228) since 2024.
Source: AI Health Index, September 2026
Questions buyers ask
How are Schrödinger and XtalPi priced and sold?
As a listed company Schrödinger reports software revenue, customer metrics and pipeline spend, which describes its own economics rather than what a licensee pays.
Listed in Hong Kong, XtalPi reports segment revenue: about 266 million yuan in 2024, with robotics the larger line. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
How do Schrödinger and XtalPi handle patient data?
In Schrödinger's case, patient data does not enter the platform; the company's separate clinical trial policy covers participants in its own trials.
For XtalPi, the website legal statement covers personal information that visitors volunteer, such as name, email address or phone number, and promises a privacy policy. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
How much do Schrödinger and XtalPi leave to the clinician?
With Schrödinger, the decision to make a molecule stays with the customer's scientists.
In XtalPi's case, the workflow is built for scientists to supervise and steer, and human scientists invoke its models and capabilities through the hub. What it automates is laboratory work and design choices rather than decisions about patients, and partners keep their own roles: META Pharmaceuticals led target research on MP-5342, and PharmaEngine is advancing PEP08 through Phase I. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Drug Discovery AI page.
Both records were reviewed on this site in September 2026. Neither publishes prices.
Ask both who owns the data and models generated during your program, and whether your results train models used for others.